January 31, 2022
Moderna’s COVID-19 vaccine has become the second to receive full approval from the U.S. Food and Drug Administration (FDA).
On Monday, the FDA announced it had given full approval to Moderna’s vaccine, which will be marketed as Spikevax for the prevention of COVID-19 in people 18 and older. The vaccine is administered as a two-dose series, one month apart.
The FDA said the approval follows a thorough evaluation of the data related to the safety, effectiveness, and manufacturing quality of the vaccine.
“While hundreds of millions of doses of Moderna COVID-19 vaccine have been administered to individuals under emergency use authorization, we understand that for some individuals, FDA approval of this vaccine may instill additional confidence in making the decision to get vaccinated,” said Acting FDA Commissioner Janet Woodcock, MD.
The vaccine is second to receive full FDA approval after Pfizer’s Comirnaty vaccine was approved during August.
Here’s what you should know:
HAP urges members of the general public who have not received the vaccine or are eligible for a booster dose to make an appointment. The available vaccines are free, safe, and effective, and provide strong protection against severe outcomes of COVID-19.
If you have questions or concerns, don’t hesitate to contact your health care provider for more information. Vaccine appointments can be found online.
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.